What 8 Analyst Ratings Have To Say About Stoke Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Stoke Therapeutics (NASDAQ:STOK) received 5 bullish, 2 somewhat bullish, and 1 indifferent analyst ratings. The average 12-month price target for the stock is $25.5, with a high of $35.00 and a low of $12.00. The average price target has increased by 75.86% over the past month.
June 26, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stoke Therapeutics received positive analyst ratings in the last quarter, with an average 12-month price target of $25.5, up 75.86% in the past month.
The majority of analyst ratings for Stoke Therapeutics are bullish or somewhat bullish, indicating a positive outlook for the stock. The average 12-month price target has increased significantly over the past month, suggesting that analysts are becoming more optimistic about the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100